Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 25
Tirzepatide vs care in early T2D at 2 years
A 2-year trial in Annals of Internal Medicine finds tirzepatide reduces HbA1c and weight more than intensified conventional care in early T2D.
Tirzepatide vs semaglutide: meta-analysis
A 2026 meta-analysis in Clinical Obesity pooled head-to-head and indirect trial data comparing tirzepatide and semaglutide for weight loss.
Is CJC-1295/ipamorelin flushing normal?
Facial flushing after CJC-1295 and ipamorelin injections is a known, documented reaction pattern for this peptide class, not an unusual one.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
What is KLOW? The peptide blend, explained
KLOW mixes BPC-157, TB-500, GHK-Cu, and KPV. Here is what the evidence for each ingredient shows, and why none of it answers a fracture-healing question.
PT-141 for low libido on GLP-1 drugs
Reduced libido is a reported side effect on GLP-1 drugs. Here is what the evidence shows for PT-141 (bremelanotide) and kisspeptin as options for women.
Retatrutide and DKA in type 1 diabetes
A Cureus 2026 case report: a type 1 diabetes patient self-injected online-sourced retatrutide and developed impending DKA alongside a Shigella infection.
A nasal spray for semaglutide? Not yet
Sydney researchers built a needle-free nasal nanocarrier for semaglutide and tested it in cells and animals, not yet in people.
Semaglutide review: weight loss and CRP
A pooled review of nine trials found subcutaneous semaglutide cut body weight and C-reactive protein versus placebo in adults with overweight or obesity.
Semaglutide and CRP in obesity: 2026 data
A 2026 meta-analysis of nine trials found semaglutide cut body weight 12% and C-reactive protein 41% versus placebo in non-diabetic adults with obesity.
Semax for ADHD: evidence in young adults
Semax modulates BDNF and dopamine signalling in animal studies. It has no approved use for ADHD and no published safety data in adolescents or young adults.